405 related articles for article (PubMed ID: 27248324)
1. Dual targeting of PI3K and MEK enhances the radiation response of K-RAS mutated non-small cell lung cancer.
Toulany M; Iida M; Keinath S; Iyi FF; Mueck K; Fehrenbacher B; Mansour WY; Schaller M; Wheeler DL; Rodemann HP
Oncotarget; 2016 Jul; 7(28):43746-43761. PubMed ID: 27248324
[TBL] [Abstract][Full Text] [Related]
2. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair.
Toulany M; Kasten-Pisula U; Brammer I; Wang S; Chen J; Dittmann K; Baumann M; Dikomey E; Rodemann HP
Clin Cancer Res; 2006 Jul; 12(13):4119-26. PubMed ID: 16818713
[TBL] [Abstract][Full Text] [Related]
3. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
4. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
5. ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition.
Toulany M; Minjgee M; Saki M; Holler M; Meier F; Eicheler W; Rodemann HP
Cancer Biol Ther; 2014 Mar; 15(3):317-28. PubMed ID: 24351425
[TBL] [Abstract][Full Text] [Related]
6. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response.
Choi EJ; Ryu YK; Kim SY; Wu HG; Kim JS; Kim IH; Kim IA
Mol Cancer Res; 2010 Jul; 8(7):1027-36. PubMed ID: 20587532
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of PI3 kinases enhances the sensitivity of non-small cell lung cancer cells to ionizing radiation.
Zhang T; Cui GB; Zhang J; Zhang F; Zhou YA; Jiang T; Li XF
Oncol Rep; 2010 Dec; 24(6):1683-9. PubMed ID: 21042768
[TBL] [Abstract][Full Text] [Related]
8. Response of non-small cell lung cancer cells to the inhibitors of phosphatidylinositol 3-kinase/Akt- and MAPK kinase 4/c-Jun NH2-terminal kinase pathways: an effective therapeutic strategy for lung cancer.
Lee HY; Oh SH; Suh YA; Baek JH; Papadimitrakopoulou V; Huang S; Hong WK
Clin Cancer Res; 2005 Aug; 11(16):6065-74. PubMed ID: 16115952
[TBL] [Abstract][Full Text] [Related]
9. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
Konstantinidou G; Bey EA; Rabellino A; Schuster K; Maira MS; Gazdar AF; Amici A; Boothman DA; Scaglioni PP
Cancer Res; 2009 Oct; 69(19):7644-52. PubMed ID: 19789349
[TBL] [Abstract][Full Text] [Related]
10. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.
Park KS; Oh B; Lee MH; Nam KY; Jin HR; Yang H; Choi J; Kim SW; Lee DH
Cancer Lett; 2016 Mar; 372(1):75-81. PubMed ID: 26723875
[TBL] [Abstract][Full Text] [Related]
11. Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells.
Holler M; Grottke A; Mueck K; Manes J; Jücker M; Rodemann HP; Toulany M
PLoS One; 2016; 11(5):e0154745. PubMed ID: 27137757
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
[TBL] [Abstract][Full Text] [Related]
13. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
14. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
[TBL] [Abstract][Full Text] [Related]
15. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.
Toulany M; Kehlbach R; Florczak U; Sak A; Wang S; Chen J; Lobrich M; Rodemann HP
Mol Cancer Ther; 2008 Jul; 7(7):1772-81. PubMed ID: 18644989
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the PI3-kinase/Akt pathway induce mitotic catastrophe in non-small cell lung cancer cells.
Hemström TH; Sandström M; Zhivotovsky B
Int J Cancer; 2006 Sep; 119(5):1028-38. PubMed ID: 16570272
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition.
Toulany M; Mihatsch J; Holler M; Chaachouay H; Rodemann HP
Radiother Oncol; 2014 May; 111(2):228-36. PubMed ID: 24857596
[TBL] [Abstract][Full Text] [Related]
18. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
19. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
Janmaat ML; Rodriguez JA; Gallegos-Ruiz M; Kruyt FA; Giaccone G
Int J Cancer; 2006 Jan; 118(1):209-14. PubMed ID: 16003751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]